Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

13th World Multispecifics Summit

4th Extracellular Vesicle-Based Therapeutic Development Summit

Mirati heads for FDA verdict on KRAS drug with new data

Roche trumpets new glofitamab data in lymphoma at ASCO

J&J, Legend get EU nod for myeloma CAR-T Carvykti

Opdualag

BMS_sign

News/ News/ Oncology

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

Phil Taylor Bristol-Myers Squibb, favezelimab, LAG-3, Merck & Co, Opdivo, Opdualag, regulatory approval, relatlimab 0 Comment

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer

X

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

https://pharmaphorum.com/news/bms-gets-fda-ok-for-first-lag-3-checkpoint-inhibitor/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Biotech founder arrested in US amid murder-for-hire investigation
Roche trumpets new glofitamab data in lymphoma at ASCO
Akili partners with gaming giant Roblox on ADHD therapy delivery
Mirati heads for FDA verdict on KRAS drug with new data
FDA clears new first-line use for Servier's Tibsovo in AML

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com